{
    "nct_id": "NCT03856216",
    "official_title": "Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation",
    "inclusion_criteria": "* Participants age 12 to 75.\n* English and non-English speaking participants are eligible.\n* CD22+ lymphoid malignancies including B-ALL\n* Eligible to receive a reduced-intensity alloSCT\n\nParticipants with:\n\n* Indolent lymphoma participants who failed conventional treatment; or,\n* Acute lymphoblastic leukemia (ALL), aggressive lymphoma, indolent lymphoma in transformation, or those who have failed ≥ three small molecule inhibitors\n* Donor: HLA compatible (8/8 match) related or matched unrelated donor (HLA-A, B, C, DRB1) or mismatched MUD (7/8 match) or haploidentical\n* Performance status of 0 to 2, Lansky ≥ 80 for < 16 years and Karnofsky ≥ 80 for ≥ 16 years of age.\n* Adequate organ function at time of study entry\n\n  1. Creatinine less than or equal to 1.6 mg/dL\n  2. Bilirubin less than 1.6 mg/dL\n  3. SGPT < 2 x UL\n  4. Ejection fraction >/= 40%\n  5. FEV1, FVC and cDLCO >/= 40%\n* Negative Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women.\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Human immunodeficiency virus (HIV) positive.\n* Prior autologous transplant less than 1 year prior to consent.\n* Active and uncontrolled disease/infection.\n* Unable or unwilling to sign consent.\n* Current active hepatic or biliary disease (with exception of Gilbert's syndrome).\n* Active hepatitis B or C.\n* Recent systemic chemotherapy or radiation within 3 weeks of study entry (intrathecal therapy is allowed).\n\nStandard biological agents such as rituximab, TKIs such as ibrutinib and venetoclax are allowed to be given within 3 days prior to receiving inotuzumab ozogamicin. Blinatumomab is allowed to be given until 1 week prior to Day -13 inotuzumab ozogamicin on study.\n\n* Prior inotuzumab ozogamicin within 3 weeks of study entry.\n* Peripheral blast count of greater than 10 K/mL.\n* QTcF interval > 470 ms.\n* Participants with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.",
    "miscellaneous_criteria": ""
}